1. Biosensors
Our focus on improving patient outcomes today while driving the development of tomorrow’s next-generation medical technology is what brings our mission to life. From pioneering beginnings to a promising pipeline, at Biosensors our success is due to our focus on research and development, clinical excellence and our talented team.
Through our high quality medical devices, we impact the lives we touch, and we are committed to continue investing in and developing pioneering medical technology, pharmacological research, and engineering new medical devices that will further benefit our patients.
This will create the greatest possible patient outcomes, and provide value to our stakeholders including physicians, shareholders and employees.
Since 1990, we have been developing and marketing critical care catheter systems and related devices used during heart surgery and intensive care treatment.
Always seeking to be at the forefront of product innovation, we entered the interventional cardiology market in 2000 with our proprietary coronary stent and accompanying stent delivery system. In the same year, we further expanded our product line to include angioplasty balloons and catheters.
In just two years, Biosensors has received CE Mark approvals for the first version of its BioMatrix™ drug-eluting stent (January 2008), its smaller-diameter (2.25 mm) version (March 2009) and finally the BioMatrix Flex™ (January 2010). The BioMatrix Flex™ stent has been approved for a comprehensive range of indications, including STEMI, Acute Coronary Syndromes and Diabetes Mellitus.
Our abluminal drug-eluting stent system is a unique combination of our proprietary anti-restenotic BA9™ (Biolimus A9™) drug and biodegradable PLA polymer.
Together with an advanced and highly flexible stent platform designed for enhanced deliverability, it offers a true next-generation solution for patients everywhere.
2. Transcu Group Limited
Transcu Group Limited is a Life Sciences company which engages in the research, development and commercialisation of cutting-edge technologies to improve and enhance the quality of life. Established in 1988 in Japan and headquartered in Singapore, the Group has offices in Singapore, Japan and the United States.
As a knowledge-based company, Transcu holds patents for at least three device inventions and has over 500 live filings for patents applications and formulations worldwide. Transcu has already succeeded in generating revenues from licensing its proprietary technologies to strategic business partners and anticipates sustainable revenues from manufacturing, distribution and sale of end-products using its proprietary technologies.
3. Raffles Medical Group (RMG)
Raffles Medical Group (RMG) is a leading medical group and the largest private group practice in Singapore. As a fully integrated healthcare organisation, the Group owns and operates a network of family medicine clinics, a tertiary care private hospital, insurance services and a consumer healthcare division. Patients of the Group enjoy a continuum of care, from having their most basic healthcare needs met through the Group’s islandwide network of Raffles Medical clinics, to specialist and tertiary care at Raffles Hospital.
Founded in 1976 with two clinics in central Singapore, RMG has grown consistently over the years to serve over one million patients today and 5,500 corporate clients including local and multi-national corporations and government agencies.
Raffles Medical Group operates a network of 74 multi-disciplinary clinics across Singapore, and four medical centres in Hong Kong and Shanghai. The Group also manages the airport clinics in Singapore’s Changi International Airport and Hong Kong’s Chek Lap Kok International Airport.
The Group’s flagship, Raffles Hospital, is a tertiary hospital. Located in the heart of Singapore, Raffles Hospital offers a full complement of specialist services combined with advanced medical technology. Its 20 specialist centres meet a wide variety of medical needs such as obstetrics and gynaecology, cardiology, oncology and orthopaedics.
As an extension of its healthcare services, the Group offers health financing under its subsidiary International Medical Insurers (IMI).
The Group’s healthcare insurance specialist writes health insurance policies for both corporate groups and individuals. IMI is able to leverage on RMG's healthcare network to provide a seamless and superior service, where the health insurer and the healthcare provider are two halves of one integrated unit.
Raffles Health, the Group’s consumer healthcare division, develops and distributes a full range of nutraceuticals, supplements, vitamins and medical diagnostic equipment for personal healthcare in Singapore and in the regional markets.
Raffles Medical Group subscribes to the Institutional Group Practice Model, a mode of practice adopted by internationally renowned US medical institutions such as the Mayo Clinic. Through this model, specialists work as a team to provide patients the quality assurance of medical services that are integrated, peer reviewed and medically audited.
http://www.rafflesmedicalgroup.com/
Posts
